Tel.: 514-340-8288
tmuanza@jgh.mcgill.ca
Dr. Thierry M. Muanza
 
Investigator, Lady Davis Institute
Radiation Oncologist, Jewish General Hospital
Radiation Oncologist, McGill University Health Centre/Montreal General Hospital
Associate Professor, Departments of Oncology, Neurology & Neurosurgery, McGill University
Associate Member, Department of Experimental Medicine, McGill University
 
Dr. Thierry Muanza is an Associate Professor in the Department of Oncology of the Faculty of Medicine at McGill University. He is also the co-Medical Director of the Adolescent and Young Adult Oncology Program. Following a Master’s degree in Biomedical Sciences from Northeastern University in Boston, Dr. Muanza obtained his M.D. from the Université de Sherbrooke. He subsequently pursued a residency at McGill University, as well as a translational research fellowship, ASTRO-NCI, in radiation oncology in Bethesda, Maryland.

Major Research Activities

Dr. Muanza’s laboratory work focuses on translational research, radio-oncology, molecular targeted therapies, and biomarkers.

Recent Publications

Xu YZ, Heravi M, Thuraisingam T, Di Marco S, Muanza T, Radzioch D. Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1. Mol Cancer. 2010 Aug 5;9:210. PubMed PMID: 20687958; PubMed Central PMCID: PMC2924311.

Heravi M, Rachid Z, Goudarzi A, Schlisser A, Jean-Claude BJ, Radzioch D,Muanza TM. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anticancer Drugs. 2009 Sep;20(8):659-67. PubMed
PMID: 19581798.

El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy E, Muanza T, Melançon D, Kavan P, Guiot MC. Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J Neurosurg. 2009 Aug;111(2):265-71. PubMed
PMID: 19284232.
Support research at the Lady Davis Institute - Jewish General Hospital